As the Supreme Court debates the constitutionality of the Patient Protection and Affordable Care Act, some states are taking a wait-and-see attitude on health insurance exchange implementation, while others are forging ahead. Meanwhile, private exchanges are gaining some traction.
As the Supreme Court debates the constitutionality of the Patient Protection and Affordable Care Act, some states are taking a wait-and-see attitude on health insurance exchange implementation, while others are forging ahead. Meanwhile, private exchanges are gaining some traction.
In a webinar that is archived here the National Institute for Health Care Management (NIHCM) discussed emerging models of public and private health insurance exchanges with a panel of experts from Booz & Company, WellPoint Health Care Service Corporation and Leavitt Partners.
The webinar included an overview of Bloom Health’s defined contribution arrangements and private exchanges. Bloom Health works with employers to set defined contribution levels, then presents employees with a platform to purchase their care.
“What you see is employers usually setting the cost or the expenses around 70-80% of the total cost of the plan and using that as a benchmark to establish a defined contribution,” said Jeffrey Welch, divisional vice president of Consumer Markets, Health Care Service Corporation. “As employees go through the tool and are educated in the process, we’ve seen 69% of the participants are choosing a higher deductible.”
Go back to the Managed Healthcare Executive eNews newsletter.
Briana Contreras, an editor of Managed Healthcare Executive, spoke with Fred Turner, CEO of Curative, in this month’s episode about the challenges middle-class Americans face in dealing with medical debt, exploring the causes behind it and the impact on overall health.
Listen
Independent Assessment of Syfovre Needed, Argues JAMA Ophthalmologist Viewpoint
December 7th 2023A California retinal specialist argues in a JAMA Ophthalmology viewpoint article that an independent panel of retinal specialists and statisticians should assess the data from clinical trials of Syfovre (pegcetacoplan) because of the lack of a complete FDA scientific analysis of the drug and of peer-reviewed publication.
Read More
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen